|
|
 |
|
Viewing report
|
|
|
|
Systemic Fungal Infection Therapeutics Market- Taiwan
Frost & Sullivan, Nov 2009, Pages: 40
This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Taiwan.
This Frost & Sullivan research service titled Systemic Fungal Infection Therapeutics Market - Taiwan provides an update on the epidemiology of systemic fungal infection (SFI), current diagnostic and treatment practices, as well as the market landscape in terms of major participants and future trends. This study is aimed at supporting manufacturers involved in the sphere of SFI treatment in decision making as well as identifying and prioritizing opportunities in Taiwan.
Market Overview
Advancements in Diagnostic Tests Pave the Way for More Targeted Approaches to Treatment in the Systemic Fungal Infection Therapeutics Market in Taiwan
With fast-paced advancements in technology, the number of patients diagnosed with SFI is expected to increase steadily over the next five years. The high incidence of SFI is largely attributed to the widespread use of broad-spectrum antibiotics, which reduces non-pathogenic bacterial population competing with fungi, and the growing number of persons with compromised immune systems caused by AIDS, immunosuppressant drugs, and chemotherapy agents. Early diagnosis of SFIs has been shown to be critical to treatment outcome. 'In Taiwan, the advent of advanced molecular diagnostic technologies, such as Galactomannan, has resulted in a shift from empiric and prophylactic therapy to a more targeted and pre-emptive therapy,' notes the analyst of this research service. 'Alongside these developments, the high premium on products that are capable of emergent problematic pathogens is poised to transform market dynamics.' Diflucan Oral and Diflucan IV remain the most popular drugs for treating SFI. Despite the competition from other drugs such as Conventional Amphotericin B and Vfend IV, Diflucan is still the choice of most specialists. Costs are decreasing, as new products are expected to enter the market in the near future, together with possible generics as some patents are set to expire. In terms of the diagnostic technology available, physicians expect more fungal culture and serology tests to be utilized in the country.
Although key therapeutics have been in the market to treat the most causative pathogen (Candida Albicans), there is an unmet need to treat more resistant ones such as Aspergillus. 'As more resistant pathogens in SFI emerge, the focus of treatment is directed toward finding the most appropriate mode of treatment in line with universal criteria, such as risk factors, clinical, radiological, microbiological or other diagnostic evidence,' says the analyst. 'The task is made easier for physicians with the growing availability of non-microbiologic and clinical diagnostic techniques, such as Platelia, Fungitell and PNA FISH, to identify the onset of infection.' Greater emphasis is placed on matching antifungal choice to pathogen susceptibility, thereby heightening the demand for rapid typing of pathogens to ensure informed and targeted drug choices. As a result, there is a reduction in the use of prophylaxis in the ‘at-risk’ patient group and empiric therapy, for example, in patients with a persistent fever or other suggestive symptoms.
Considering the niche nature of SFI, it is imperative for major participants to differentiate their products, especially as advancements in diagnostic techniques bring about a restriction of prescriptions to specific therapeutic uses. The market is witnessing a shift in therapeutics from broad and empiric indications. Hence, pharmaceutical manufacturers must position their products to address more specific indications defined by pathogen species and sub species as well as patient population Drug development for SFI therapeutics must target certain pathogens, rather than a broad spectrum to achieve greater differentiation and protect the drug from generic erosion in the future. The changing epidemiology of causative pathogens has caused the effectiveness of existing therapeutic options to decline. Pharmaceutical manufacturers must develop drugs that address specific indications in terms of pathogen coverage and patient groups i.e. solid organ transplant, cancer, neonates, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), and surgical patients.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Systemic Fungal Infection Therapeutics Market - Australia
Systemic Fungal Infection Therapeutics Market Research – Philippines
Systemic Fungal Infection Therapeutics Research – Malaysia
Systemic Fungal Infection Therapeutics Market - South Korea
Systemic Fungal Infection Therapeutics Market – Singapore
Systemic Fungal Infection Therapeutics Market – China
Systemic Fungal Infection Therapeutics Market – India
Systemic Fungal Infection Therapeutics Market – Thailand
Systemic Fungal Infection Therapeutics Market - Hong Kong
Personalized Medicine - Scientific and Commercial Aspects
|
|
|
|
